tgfbdnrii-transduced autologous tumor infiltrating lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2017 (NCT02650986)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tgfbdnrii-transduced autologous tumor infiltrating lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02650986 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1